Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Aspirin dilemma: to stop or not to stop during brain bleed treatment?

NCT ID NCT07240454

Disease control Sponsor: Tao Liu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with a chronic subdural hematoma (a slow brain bleed) who are already taking aspirin should continue or stop it while receiving non-surgical care. Researchers will follow 143 participants for 6 months to see if the hematoma comes back or worsens. The goal is to provide better guidance on managing aspirin use in this situation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aspirin
What this could lead to
If it works, this could help doctors give clearer guidance on whether to keep taking aspirin during conservative treatment for chronic subdural hematoma, potentially reducing the risk of the hematoma coming back or getting worse.
What could go wrong
This is a relatively small trial (143 people) and is not a late-stage study, so results may not apply to everyone. The main risk is that continuing aspirin might increase bleeding, while stopping it could raise the chance of a heart attack or stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 143 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years, male or female; * Confirmed diagnosis of chronic subdural hematoma (cSDH) by cranial CT and/or MRI; * Intended for conservative management (i.e., no surgical evacuation indication at enrollment); * Regular aspirin use at enrollment; * Informed consent signed by the patient or legal representative. Exclusion Criteria: * Patients requiring emergency surgery to remove hematoma at enrollment; * Concurrent use of other anticoagulants or antiplatelet agents that cannot be discontinued according to the study protocol; * cSDH secondary to other diseases or conditions (e.g., excessive drainage from ventriculoperitoneal shunts, intracranial tumors); * Active bleeding events or major cardiac events (e.g., acute myocardial infarction, unstable angina, or revascularization surgery) within 30 days prior to enrollment; * Known bleeding disorders (e.g., hemophilia, severe thrombocytopenia); * Individuals unable to provide informed consent or for whom completion of follow-up is anticipated to be difficult.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic subdural hematoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic subdural hematoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, China

  • Xuanwu Hospital Capital Medical University

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.